163.1 ð é«åžçç
163.1.0.1 ð äžé éé»
- Haemophilus species:
- H. influenzae â most clinical relevance
- Type b (Hib): éå» meningitis/epiglottitis #1 in < 5 yr; Hib vaccine å€§å¹ æž
- Non-typeable (NTHi): AOM, sinusitis, COPD exacerbation, conjunctivitis, neonatal sepsis
- H. parainfluenzae: HACEK IE
- H. ducreyi: chancroid (ç genital ulcer + LAP)
- H. influenzae â most clinical relevance
- Moraxella catarrhalis: AOM, sinusitis, COPD exacerbation
- Microbiology: å€§å€ gram - coccobacilli; H. influenzae é X + V factors (chocolate agar); H. ducreyi é nutritious + X factor
- Treatment:
- β-lactamase prevalence é« (NTHi 25-40%, M. catarrhalis ~ 90-100%)
- Amoxicillin-clavulanate, 2nd/3rd gen ceph (ceftriaxone), FQ, macrolide
163.1.0.2 1ïžâ£ Haemophilus influenzae
163.1.0.2.1 现èåž
- Gram - coccobacillus
- Fastidious â é X factor (hemin) + V factor (NAD) â chocolate agar
- 6 capsular serotypes (a-f); type b (Hib) = past major pathogen
- Non-typeable (NTHi): ç¡ capsule, 廣 mucosal pathogen
163.1.0.2.2 Hib (Type b)
- Past meningitis #1 cause in < 5 yr (pre-vaccine, 1985)
- Epiglottitis (âcherry red epiglottisâ, airway emergency)
- Cellulitis (face, buccal â characteristic violaceous)
- Septic arthritis, osteomyelitis in children
- Bacteremia, pneumonia, occult fever
- Hib vaccine (conjugate, PRP-T/HbOC/PRP-OMP) â 1990s onwards, 99% reduction
- Dose: 2, 4, 6, 12-15 mo
163.1.0.2.3 NTHi (Non-typeable H. influenzae)
- AOM (small child, after pneumococcus)
- Sinusitis (acute bacterial)
- COPD acute exacerbation (#1 bacterial cause)
- CAP (especially elderly, COPD)
- Conjunctivitis
- Neonatal sepsis (vertical), maternal chorioamnionitis
163.1.0.2.4 æ²»ç
- Amoxicillin if β-lactamase neg (decreasing %)
- Amoxicillin-clavulanate (preferred for AOM/sinusitis empiric â β-lactamase coverage)
- 2nd gen ceph (cefuroxime), 3rd gen (ceftriaxone) for severe
- Macrolide (azithromycin), Doxycycline, FQ (levofloxacin) alternatives
- Meningitis: ceftriaxone 2 g q12h à 7d (Hib) + dexamethasone (especially child)
163.1.0.3 2ïžâ£ Haemophilus ducreyi (Chancroid)
- ç±åž¶ STI; declining globally but still endemic Africa, Caribbean, S. America
- ç genital ulcer (vs syphilis painless chancre) + tender suppurative LAP (bubo)
- Co-infection with HIV common (genital ulcer increase HIV risk)
- Dx: clinical + culture (specific media, hard); PCR if available
- Treatment:
- Azithromycin 1 g PO Ã 1
- Ceftriaxone 250 mg IM Ã 1
- Ciprofloxacin 500 mg PO bid à 3d
- Erythromycin 500 mg PO qid à 7d
- HIV + immunosuppression â response slower, may need longer
- Partner treat 10d window
163.1.0.3.1 éå¥ â Genital Ulcer
| ç | ç | LAP |
|---|---|---|
| Syphilis (chancre) | äžç | Painless ± |
| HSV | ç (multiple) | Tender + |
| Chancroid (H. ducreyi) | ç (deep) | Tender, suppurative |
| LGV (C. trachomatis L1-3) | Painless | Tender, suppurative (groove sign) |
| Granuloma inguinale (Klebsiella granulomatis) | Painless beefy | ± |
163.1.0.4 3ïžâ£ H. parainfluenzae + HACEK IE
- HACEK = H. parainfluenzae, Aggregatibacter actinomycetemcomitans/aphrophilus, Cardiobacterium, Eikenella, Kingella
- Gram - fastidious; ~ 1-3% all IE
- Slow-growing (4 wk hold + 5-7 d) â modern automated blood culture detects in 5 days
- Subacute IE, native valve, normal mouth flora (some HACEK çéœ reservoir)
- Treatment: ceftriaxone 2 g IV q24h à 4 wk (native) / 6 wk (prosthetic)
- Ampicillin-sulbactam alt
- Cure rate high (90%+)
163.1.0.5 4ïžâ£ Moraxella catarrhalis
- Gram - diplococcus (å Neisseria çèµ·äŸ)
- Oxidase + (å Neisseria)
- DNAse + (éå¥ Neisseria DNase -)
- Carrier æ®é (40%+ small children)
- 100% β-lactamase positive (BRO-1, BRO-2)
- èšåº:
- AOM (3rd cause after pneumococcus, NTHi)
- Sinusitis
- COPD acute exacerbation
- Pneumonia (elderly, immunocompromise, COPD)
- Treatment:
- Amoxicillin-clavulanate (β-lactamase covered)
- 2nd/3rd ceph, macrolide, doxy, FQ
- Plain amoxicillin/ampicillin æ²çš (β-lactamase)